Overview
| Name | OpenDDE · aliases: OpenDDE |
|---|---|
| Full name | Open Drug Discovery Engine |
| Ambiguous names (not auto-linked) | DDE |
| Family | Not a family entry. Covers the open OpenDDE weights only; the company's internal antibody design model is related but different |
| Organization | Aureka AI Research, Aureka Biotechnologies |
| Organization type | AI-native biotech |
| Country | United States, China |
| Model class | Co-folding (antibody-leaning) |
| Domain | Structure & co-folding (also: Antibodies) |
| First release | · preprint Basis: arXiv technical report (the HF card notes a 07-03 preview; public announcement 07-06) source |
| Other milestones | |
| Latest update | · code release Basis: GitHub release 1.2.0 1.2.0 adds constraint-guided inference with examples, after 1.1.0 (2026-08-16) and several 1.0.x releases source The most recent sourced event, not a claim that nothing changed since. |
| Status | Active · Shipping releases through its first year |
| Openness | Code: Open · Apache-2.0 Weights: Open · Apache-2.0 Code, weights and benchmarks all ship under Apache-2.0, making it a fully reproducible counterpart to closed engines |
| Benchmarks reported | 1 counted (modified protocol 1, unconfirmed 1) |
| Wet-lab validation | None recorded |
| Unverified fields | † benchmarks_reported[1], background.funding |
| As of | 2026-11-16 |
What it does
An all-atom biomolecular foundation model that predicts protein, nucleic-acid and small-molecule complexes as the entry point of a planned discovery engine, tuned for antibody-antigen generalisation. Unlike the proprietary weights of Protenix or the closed IsoDDE, it releases training code, inference pipeline, checkpoints and benchmarks together.
Benchmarks reported
Every row is one pairing from the survey's relation file; a score belongs to the benchmark page's ranking, where it is shown with metric, eval set, source type and date. 1 of 2 pairings are counted.
| Benchmark | Relation | Eval set / protocol | Source type | Note and evidence |
|---|---|---|---|---|
| 31 FoldBench | Developer report, modified protocol | self-defined FoldBench antibody-antigen subset | Self-reported | Self-defined FoldBench-AB antibody-antigen subset; not comparable to official board · evidence |
| 36 AIntibody | Unconfirmed (not counted) | Challenge 1 (computational affinity maturation) | Unconfirmed source | The placement belongs to that company's internal model and cannot be credited to the open weights; the site matrix and model page disagree. †disputed · evidence |
Other evaluations (outside the 44)
- Self-built antibody evaluation sets (self report) Self-reported: The report also self-reports on two antibody evaluation sets, one partly self-built, each under both a top-ranked and an oracle selection protocol
- The competition paper's overall finding (third party reading) Third-party: The AIntibody paper concludes computational design did not beat experimental methods overall; the press release's wording overstates it
- The open-version claim (second hand) Third-party: The claim that this is the open version of the internal model appears only in a company release and one second-hand article, never in the report or repository
Developers report: Developers report the first fully open co-folding model at closed-engine level, leading on antibody-antigen tasks (self-reported, on partly self-built sets).
Independent evidence: No independent evidence found. Only self-reported tables exist; no third-party rerun found
Training data
Group in Figure 7: Public data only.
| Class | Value | Detail |
|---|---|---|
| a. Public databases | Yes | Weighted PDB, AFDB-multimer, distillation data, MGnify, Swiss-Prot and SAbDab source |
| b. Private or licensed data | Not disclosed | The paper does not mention private or licensed data source |
| c. Own wet-lab data used for training | No | Not mentioned in the paper; the company has a high-throughput wet lab and calls the feedback loop a later feature source |
| d. Wet lab used only for validation | No |
Wet-lab validation
None. The developers report no wet-lab validation.
Background
- Organization: Aureka Biotechnologies was founded in 2023, headquartered in Laguna Hills, California with a Shanghai team; an AI-native biotech running a dry-wet closed loop plus its own pipeline, with headcount undisclosed.
- Funding: A Series A in 2025-11 (amounts differ across second-hand sources), a $35M Series A+ on 2026-04-28, and a $100M Series B announced 2026-08-10, bringing the total to nearly $200M.
- Products and partnerships: Open-sources this model as a design-engine module, runs its own cardiometabolic, immunology and CNS pipeline, and is building a new wet lab in Irvine; no pharma partnership disclosed.
- Related models: IsoDDE, Protenix, ESMFold2
Reading notes
- The antibody figures are high but partly rest on self-built sets and need independent replication.
- Each antibody evaluation comes in two selection protocols; any citation must say which one.
- Without PoseBusters or Runs N' Poses there is no comparison of small-molecule pose accuracy.
- Openness is its firmest advantage: the only fully reproducible engine-level counterpart.
Caveats
- The competition placing belongs to the internal model, not these weights; the pairing remains an open inconsistency (unverified).
- The open-version framing rests on company wording plus one second-hand article.
- The report is internally inconsistent about one baseline model's values.
- The company calls the wet-lab feedback loop a later feature; this version uses no in-house data.
Sources
- OpenDDE technical report (preprint) ·
- OpenDDE GitHub releases (repository)
- Hugging Face weights (repository)
- Antibody design competition paper (journal)
- Press report on the open module and the company (press)
- Syndicated company press release (second-hand) (second-hand) second-hand
Corrections
1 correction
| Field | Was | Now | Basis | Found |
|---|---|---|---|---|
| benchmarks_reported.bench-36-aintibody | The matrix marked it as an official board entry | Changed to unconfirmed: the placing belongs to the company's internal antibody model, not these weights (unverified) | source | 2026-11-16 |
Part of the AI for Bio benchmarks survey · all 112 models · open in the explorer. Record as of 2026-11-16.